Acute Urinary Retention

1. Clinical Overview

Summary

Acute urinary retention (AUR) is the sudden and painful inability to pass urine despite a full bladder, representing a urological emergency requiring immediate bladder drainage. [1] It is characterised by a palpable or percussable bladder, patient distress, and complete inability to void voluntarily. The condition affects predominantly elderly men, with benign prostatic hyperplasia (BPH) being the underlying cause in 53-70% of cases. [2,3] AUR may occur spontaneously or be precipitated by identifiable factors including medications, constipation, urinary tract infection, or recent surgery. Prompt catheterisation provides immediate relief, but identification of the underlying aetiology and appropriate planning for trial without catheter (TWOC) is essential for definitive management.

The pathophysiology involves either mechanical bladder outlet obstruction or functional impairment of detrusor contractility, with most cases representing a combination of both. Understanding the distinction between acute retention (painful, lower volume) and chronic retention (painless, high volume, with or without upper tract involvement) is critical for appropriate management. High-pressure chronic retention with bilateral hydronephrosis represents a distinct entity requiring urgent urological input and careful monitoring for post-obstructive diuresis following catheterisation. [4]

Key Facts

Clinical Pearls

The Medication Review: Always review the drug chart. Anticholinergics, opioids, alpha-agonists (in cold remedies), antihistamines, and tricyclic antidepressants are common precipitants. A Cochrane review identified anticholinergic burden as a significant modifiable risk factor. [8]

Cauda Equina Protocol: Any patient with urinary retention plus bilateral leg symptoms, saddle anaesthesia, or faecal incontinence requires emergency MRI spine within 4 hours. Do not catheterise before neurological assessment if practicable—the post-void residual is diagnostically valuable.

The 3Ps of Precipitants: Prostate (BPH/cancer/prostatitis), Pharmacological (drugs affecting bladder or sphincter), and Poo (constipation causing extrinsic compression)—systematically address all three.

Post-Obstructive Diuresis Warning: Following catheterisation for chronic retention with high residual volumes (> 1500ml), monitor urine output hourly. Pathological diuresis (> 200ml/hr for > 2 hours) occurs in up to 50% of high-pressure retention cases and requires IV fluid replacement and electrolyte monitoring. [4,9]

Why This Matters Clinically

AUR causes immediate and significant patient distress, requiring urgent intervention. Beyond symptomatic relief, untreated retention leads to bladder overdistension, which may cause permanent detrusor damage if prolonged beyond 24-48 hours. [1] High-pressure chronic retention transmits back-pressure to the upper tracts, causing bilateral hydronephrosis and potentially irreversible renal impairment. Identification of neurological causes (cauda equina syndrome, spinal cord compression) is time-critical—delays beyond 48 hours are associated with significantly worse neurological outcomes. [10] The management of AUR also has resource implications: approximately 30-40% of men presenting with AUR will ultimately require surgical intervention, most commonly TURP. [7]

---

2. Epidemiology

Incidence and Prevalence

AUR demonstrates a strong age-dependent incidence, reflecting the progressive enlargement of the prostate with ageing in men. The Olmsted County Study, a prospective population-based cohort, remains the most robust source of incidence data. [2]

The Health Professionals Follow-up Study (n=25,000+ men) confirmed these findings, demonstrating that by age 80, nearly one-quarter of men will have experienced at least one episode of AUR. [3]

Demographics

Female AUR is rare but occurs. Causes differ from males: pelvic organ prolapse, urethral stricture, pelvic masses, postoperative (especially following pelvic surgery), and neurological conditions predominate. [11]

Risk Factors

Non-Modifiable Risk Factors:

• Age > 60 years (OR 3.5-5.0 per decade increase) [2]
• Male sex (anatomical prostate)
• Previous episode of AUR (recurrence rate 56-70%) [7]
• Neurological disease (multiple sclerosis, Parkinson's disease, spinal cord lesions)
• Prostate volume > 30ml (OR 3.0-4.0) [3]

Modifiable Risk Factors:

Precipitating Factors

A worldwide survey of 6,074 men with BPH-related AUR identified the following precipitants: [13]

---

3. Aetiology

Classification by Mechanism

AUR results from either mechanical outlet obstruction, functional detrusor failure, or a combination of both.

3.1 Obstructive Causes (Mechanical)

3.2 Non-Obstructive Causes (Functional/Detrusor Failure)

Benign Prostatic Hyperplasia: The Commonest Cause

BPH accounts for 53-70% of male AUR cases and warrants detailed understanding. [2,3]

Pathophysiology of BPH-related AUR:

The prostate undergoes progressive enlargement from the third decade, with histological BPH present in 50% of men by age 50 and 90% by age 80. [14] However, only 25-50% of men with histological BPH develop clinical symptoms (LUTS), and only a minority progress to AUR.

Two components contribute to obstruction:

1. Static component: Physical bulk of enlarged prostate tissue compressing the prostatic urethra
2. Dynamic component: Smooth muscle tone in prostatic stroma and bladder neck, mediated by alpha-1 adrenergic receptors (predominantly alpha-1A subtype)

Exam Detail: Molecular Pathophysiology of BPH:

Prostatic enlargement is driven by:

• Dihydrotestosterone (DHT) acting via androgen receptors in stromal cells
• Growth factors: FGF, EGF, TGF-beta, IGF
• Stromal-epithelial interactions promoting proliferation
• Reduced apoptosis in the transition zone

The dynamic component involves:

• Alpha-1A adrenoceptors (70% of prostatic alpha-1 receptors) in smooth muscle
• Alpha-1D adrenoceptors in detrusor and blood vessels
• Noradrenaline-mediated smooth muscle contraction

This dual mechanism explains why alpha-blockers (targeting dynamic component) provide rapid symptom relief and improve TWOC success, while 5-alpha reductase inhibitors (reducing DHT and prostate volume) require 6-12 months for maximal effect. [14]

Progression to AUR in BPH:

The Medical Therapy of Prostatic Symptoms (MTOPS) study and REDUCE trial identified predictors of AUR in men with BPH: [15]

• Prostate volume > 30ml (HR 3.5)
• PSA > 1.4 ng/ml (proxy for prostate volume; HR 2.0)
• Maximum flow rate (Qmax) less than 10.6 ml/s (HR 2.6)
• IPSS symptom score > 7 (HR 2.0)
• Age > 70 years (HR 1.5)

---

4. Pathophysiology

Normal Micturition Physiology

Exam Detail: The Micturition Reflex:

Normal voiding requires coordinated:

1. Detrusor contraction (parasympathetic, S2-S4 via pelvic nerve; muscarinic M3 receptors)
2. Internal sphincter relaxation (sympathetic withdrawal; alpha-1 adrenergic)
3. External sphincter relaxation (somatic, pudendal nerve S2-S4; voluntary control)
4. Pontine micturition centre coordination (brainstem switching from storage to voiding)

Storage phase:

• Sympathetic (T10-L2): Beta-3 receptors relax detrusor; alpha-1 receptors contract bladder neck
• Somatic: Pudendal nerve maintains external sphincter tone
• Parasympathetic: Inhibited centrally

Voiding phase:

• Pontine micturition centre activates parasympathetic outflow
• Sympathetic and somatic inhibition
• Coordinated detrusor contraction with sphincter relaxation

Mechanism of Acute Urinary Retention

Step 1: Initial Obstruction or Detrusor Failure

• Mechanical obstruction increases urethral resistance (BPH, stricture)
• OR detrusor contractility is impaired (drugs, neurological, overdistension)
• OR combination: BPH with superimposed precipitant (opioids, constipation)

Step 2: Progressive Bladder Distension

• Bladder fills beyond normal capacity (300-500ml)
• Intravesical pressure rises
• Bladder wall stretches, activating stretch receptors
• Pain fibres (A-delta and C fibres) signal distension
• Patient experiences urgency but cannot initiate voiding

Step 3: Detrusor Decompensation

• Overdistension beyond 400-600ml impairs detrusor contractility
• Myogenic damage begins if distension prolonged (> 24-48 hours) [1]
• A vicious cycle develops: more distension → weaker contractions → more retention

Step 4: Upper Tract Involvement (in chronic/high-pressure retention)

• Sustained high intravesical pressure (> 40 cmH2O) transmits to ureters
• Vesicoureteric junction overwhelmed
• Bilateral hydroureteronephrosis develops
• Renal parenchymal compression → obstructive nephropathy
• GFR declines; creatinine rises

Step 5: Post-Obstructive Diuresis (following relief)

• Accumulated urea, sodium, and water excreted
• Tubular concentrating ability impaired by chronic obstruction
• Diuresis may be physiological (appropriate fluid/solute excretion) or pathological (salt-wasting, unable to concentrate)
• Risk of hypovolaemia and electrolyte derangement

Classification of Urinary Retention

Post-Obstructive Diuresis (POD)

Post-obstructive diuresis is defined as urine output > 200ml/hr for > 2 consecutive hours or > 3L/day following relief of obstruction. [4,9]

Incidence: 0.5-52% depending on definition and population; higher in chronic high-pressure retention

Mechanisms:

Clinical Pearl: Monitoring Protocol for Post-Obstructive Diuresis:

1. Hourly urine output for first 6 hours, then 2-hourly if stable
2. Daily U&Es (or more frequently if diuresis > 200ml/hr)
3. Fluid replacement: If output > 200ml/hr, replace 50-75% of previous hour's output with 0.9% saline
4. Avoid over-replacement—this perpetuates diuresis
5. Admit if: urine output > 200ml/hr for > 2 hours, rising creatinine, electrolyte abnormalities

---

5. Clinical Presentation

Symptoms

Cardinal Symptoms of AUR:

Background LUTS (suggesting BPH):

• Weak stream (75%)
• Hesitancy (70%)
• Incomplete emptying (65%)
• Frequency/Nocturia (60%)
• Terminal dribbling (50%)

Atypical Presentations:

Signs

General Examination:

• Distressed, restless patient
• Diaphoresis (sympathetic activation)
• Tachycardia, hypertension (pain response)
• Signs of sepsis if infected (fever, rigors, hypotension)

Abdominal Examination:

• Inspection: Lower abdominal distension; visible bladder in thin patients
• Palpation: Suprapubic mass arising from pelvis; smooth, tender; cannot get below it
• Percussion: Dull to percussion above pubic symphysis (≥150ml detectable; ≥300ml reliable)

Digital Rectal Examination (DRE):

• Prostate: Size, consistency, nodularity, tenderness
• Anal tone: Reduced in cauda equina
• Rectal contents: Faecal loading

Neurological Examination (if indicated):

• Lower limb power, tone, reflexes
• Saddle sensation (S2-S4)
• Perianal sensation
• Anal wink reflex
• Bulbocavernosus reflex

Red Flags

[!CAUTION] Red Flags — Immediate action required:

Red Flag	Indicates	Action
Bilateral leg weakness + urinary retention	Cauda equina syndrome	Emergency MRI spine; neurosurgical referral
Saddle anaesthesia + faecal incontinence	Cauda equina syndrome	Emergency MRI spine within 4 hours
Bilateral hydronephrosis + raised creatinine	High-pressure chronic retention	Catheterise; monitor for POD; admit
Fever + rigors + urinary retention	Urosepsis	Sepsis six; IV antibiotics; catheterise
Post-catheter output > 200ml/hr	Post-obstructive diuresis	Fluid/electrolyte monitoring; admit
Haematuria + clots + retention	Clot retention	Three-way catheter; bladder washout

---

6. Clinical Examination

Structured OSCE Approach

Introduction and General Inspection:

• Wash hands, introduce self, confirm identity, explain examination, gain consent
• Patient position: Supine, adequately exposed from xiphisternum to mid-thigh
• General inspection: Distress, pallor, oedema, confusion, catheter in situ

Vital Signs:

• Temperature (fever suggests infection)
• Heart rate (tachycardia with pain/sepsis)
• Blood pressure (hypertension with pain; hypotension with sepsis)
• Respiratory rate
• Oxygen saturation

Abdominal Examination:

Digital Rectal Examination:

Neurological Examination (if suspicion of neurological cause):

Bedside Tests

---

7. Differential Diagnosis

Key Differentials

Must Not Miss

1. Cauda Equina Syndrome: Bilateral leg symptoms, saddle anaesthesia, faecal incontinence, urinary retention. Emergency MRI. Delay = permanent paralysis.
2. Urosepsis: Fever, rigors, hypotension with retention. Sepsis six protocol; IV antibiotics.
3. Clot Retention: Haematuria history; unable to pass clots. Three-way catheter and washout.

---

8. Investigations

First-Line (Bedside)

Laboratory Tests

Clinical Pearl: PSA in Acute Urinary Retention: PSA is falsely elevated by:

• Urinary retention (up to 6-fold increase)
• Catheterisation
• UTI/Prostatitis
• DRE (minimal effect)

Wait at least 6 weeks after resolution of retention and catheter removal before checking PSA for prostate cancer screening.

Imaging

Diagnostic Criteria

Acute Urinary Retention:

• Painful inability to void
• Palpable or percussable bladder OR
• Bladder scan volume ≥300ml

Chronic Urinary Retention:

• Painless
• Post-void residual ≥300ml (or ≥1000ml for significant chronic retention)

High-Pressure Chronic Retention:

• Chronic retention PLUS
• Bilateral hydronephrosis on imaging AND/OR
• Raised serum creatinine

---

9. Management

Management Algorithm

                    ACUTE URINARY RETENTION
                             ↓
┌──────────────────────────────────────────────────────────────┐
│              IMMEDIATE ASSESSMENT                            │
│  • Confirm retention (bladder scan > 300ml)                   │
│  • Vital signs (sepsis screen)                               │
│  • Focused history: precipitants, neuro symptoms             │
│  • Neurological examination if any concern                   │
└──────────────────────────────────────────────────────────────┘
                             ↓
                 NEUROLOGICAL RED FLAGS?
            ↙                             ↘
          YES                              NO
           ↓                                ↓
   EMERGENCY MRI SPINE             URETHRAL CATHETERISATION
   Do NOT delay for catheter       12-14F Foley first attempt
                                   Record residual volume
                             ↓
                    CATHETERISATION SUCCESSFUL?
                    ↙                        ↘
                  YES                         NO
                   ↓                           ↓
         Continue workup              DIFFICULT CATHETER PATHWAY
         Start alpha-blocker          • Senior/urology attempt
                                      • Consider: Coude catheter
                                      • Suprapubic catheter (SPC)
                             ↓
                    ASSESS FOR HIGH-PRESSURE RETENTION
                    • Residual volume > 1000ml
                    • Check U&Es urgently
                    • Renal USS within 24-48 hours
                    ↙                        ↘
           HIGH-PRESSURE                  LOW-PRESSURE
           (Hydronephrosis + ↑Cr)         (Normal renal function)
                   ↓                           ↓
        • Admit for monitoring           • Discharge with catheter
        • Monitor for POD                • Alpha-blocker (tamsulosin)
        • IV fluids PRN                  • TWOC in 2-3 days
        • Urology referral               • Urology outpatient f/u

Immediate Management (Emergency Department)

Step 1: Confirm Diagnosis

• Bladder scan: Volume > 300ml confirms retention
• Document volume for prognostication

Step 2: Exclude Neurological Emergency

• Ask: Leg weakness? Saddle numbness? Bowel incontinence?
• Examine: Lower limb neurology, saddle sensation, anal tone
• If positive → Emergency MRI spine (do not delay for catheterisation)

Step 3: Urethral Catheterisation

Procedure Detail: Urethral Catheterisation Technique (Male):

Equipment:

• Catheterisation pack (sterile drape, gauze, gallipot)
• Sterile gloves
• Antiseptic solution (0.05% chlorhexidine or saline)
• Lidocaine 2% gel (Instillagel) 11ml syringe
• Foley catheter: 12-14F initially; larger if haematuria
• 10ml syringe with 10ml sterile water (for balloon)
• Catheter bag (leg bag or drainage bag)

Technique:

1. Position patient supine; expose genitalia
2. Wash hands; open pack aseptically; don sterile gloves
3. Create sterile field with drapes
4. Retract foreskin (if present); clean glans with antiseptic (outward spiral technique)
5. Hold penis perpendicular to body (straightens urethra)
6. Instil lidocaine gel slowly into urethra; "milk" gel along urethra; wait 3-5 minutes
7. Holding penis at 60-90° to abdomen, advance catheter gently
8. At external sphincter (15-17cm), resistance may be felt—ask patient to relax/cough; gentle sustained pressure
9. At prostatic urethra (additional resistance in BPH), angle penis downwards towards feet; continue gentle advancement
10. Advance to the "Y" junction of the catheter (ensures balloon is in bladder)
11. Wait for urine drainage; inflate balloon with 10ml sterile water
12. Gently withdraw catheter until resistance felt (balloon at bladder neck)
13. Replace foreskin (prevent paraphimosis)
14. Attach drainage bag; secure catheter to thigh
15. Document: Residual volume, urine appearance, catheter size

Troubleshooting:

• Resistance at external sphincter: Wait, ask patient to bear down, apply gentle pressure
• Resistance at prostate: Angle penis downwards; try larger catheter (16F may pass easier than 12F in BPH)
• False passage: Abandon attempt; do not force; senior/urology input
• Complete failure: Suprapubic catheter (SPC)

Catheter Selection:

• 12-14F: Standard first attempt
• 16F: If some resistance; larger bore may negotiate BPH better
• Coudé tip: Angled tip for prostatic obstruction
• 3-way: If haematuria/clots (for washout)
• Silicone: Longer-term use (lower encrustation)

Step 4: Document Residual Volume

• Record exact volume drained
• Volume > 1000ml suggests chronic retention
• Volume > 1500 ml: High risk of post-obstructive diuresis

Step 5: Urine Sample

• If cloudy or dipstick positive, send MC&S
• Start antibiotics if clinically infected

Step 6: Check Renal Function

• All patients: U&Es
• If raised creatinine or volume > 1000 ml: Renal USS within 24-48 hours

Alpha-Blocker Therapy

Alpha-blockers are the cornerstone of medical management, improving TWOC success from 29-40% to 51-62%. [5,6]

Mechanism of Action: Alpha-1 adrenoceptor antagonism causes:

• Relaxation of prostatic smooth muscle (dynamic component of obstruction)
• Relaxation of bladder neck smooth muscle
• Reduced urethral resistance

Drug Selection:

Exam Detail: ALFAUR Trial (McNeill et al., 2004): [5]

• Landmark RCT: 357 men with first episode of AUR randomised to alfuzosin 10mg OD vs placebo
• TWOC at day 3
• Results: Successful TWOC in 61.9% (alfuzosin) vs 47.9% (placebo), p=0.03
• NNT = 7 (one additional successful TWOC for every 7 patients treated)
• Clinical impact: Alpha-blockers now standard of care before TWOC

Timing:

• Start alpha-blocker as soon as catheter is inserted
• Continue for minimum 2-3 days before TWOC (allows smooth muscle relaxation)
• Continue for 4-6 weeks if TWOC successful; then reassess

Trial Without Catheter (TWOC)

TWOC is the standard approach following AUR, with timing typically 2-3 days post-catheterisation.

Protocol:

1. Pre-TWOC Preparation (Day 0-2):

   • Alpha-blocker started and taken for minimum 48-72 hours
   • Address precipitants: Stop offending medications if possible; treat constipation
   • Patient counselled on procedure and expectations

2. TWOC Day:

   • Advise patient to drink normally (not excessively)
   • Remove catheter (morning preferred; allows daytime monitoring)
   • Patient must void within 6 hours
   • Perform bladder scan after void: Post-void residual (PVR) target less than 200ml

3. Outcome Assessment:

TWOC Success Predictors: [5,6,13]

Failed TWOC:

• Approximately 40-60% of first TWOC attempts fail [7]
• Options after failed TWOC:
  1. Repeat TWOC at 2-4 weeks (success rate lower, ~20-30%)
  2. Long-term catheterisation (intermittent self-catheterisation or indwelling) pending surgery
  3. Surgical intervention: TURP, HoLEP, prostatic urethral lift, or other BPH surgery

Management of High-Pressure Chronic Retention

High-pressure chronic retention (HPCR) requires specific management due to the risk of post-obstructive diuresis and renal impairment.

Identification:

• Residual volume often > 1000-1500ml
• Bilateral hydronephrosis on renal USS
• Elevated creatinine (may be markedly elevated)
• Often presents with symptoms of renal failure (malaise, nausea, confusion) rather than retention

Management Principles:

1. Catheterise promptly — Do NOT wait; obstruction relief allows renal recovery
2. Do NOT clamp catheter — Old practice of "gradual decompression" is not evidence-based and delays treatment
3. Monitor for post-obstructive diuresis:
   • Hourly urine output for 6 hours, then 2-hourly
   • Daily U&Es (or more frequently if diuresis)
   • Fluid balance chart
4. Fluid replacement:
   • If output > 200ml/hr: Replace 50-75% of previous hour's output with 0.9% saline
   • Do not over-replace (perpetuates diuresis)
   • Allow physiological diuresis to self-correct
5. Admit for monitoring — Typically 24-48 hours minimum
6. Avoid nephrotoxins — Hold NSAIDs, ACE inhibitors, metformin if creatinine elevated
7. Long-term catheter — TWOC usually not attempted in HPCR; plan for surgical intervention
8. Urology referral — All patients with HPCR need urological assessment

Surgical Management

Indications for Surgery:

• Failed TWOC (especially second failure)
• Recurrent AUR despite medical therapy
• Refractory urinary symptoms
• Chronic retention with renal impairment
• Patient preference

Surgical Options for BPH:

Other Surgical Interventions:

• Urethral stricture: Urethrotomy, dilatation, or urethroplasty
• Clean intermittent self-catheterisation (CISC): For neurogenic bladder/detrusor failure
• Suprapubic catheter: Failed urethral catheterisation; patient preference; urethral pathology

Special Populations

Postoperative AUR: [12]

• Common (15-25% after pelvic surgery; 5-10% general surgery)
• Multifactorial: Anaesthesia, opioids, immobility, fluid overload
• Management: Catheterise; usually single TWOC after 24-48 hours successful
• Prevention: Avoid excessive IV fluids; minimise opioids; early mobilisation

Women with AUR: [11]

• Rare (1:13-20 compared to men)
• Causes: Pelvic organ prolapse, pelvic mass, postoperative, urethral stricture, neurological
• Management: Catheterise; investigate for underlying cause; CISC often required

Neurogenic Bladder:

• Identify underlying cause (MS, Parkinson's, spinal cord injury, diabetes)
• CISC often the long-term solution
• Urodynamics to characterise dysfunction
• MDT approach (urology, neurology, rehabilitation)

---

10. Complications

Immediate Complications (Minutes-Hours)

Early Complications (Days)

Late Complications (Weeks-Months)

---

11. Prognosis and Outcomes

Natural History

Without Treatment:

• Progressive bladder distension and detrusor decompensation
• Overflow incontinence
• Upper tract involvement in chronic high-pressure retention
• Renal failure (obstructive uropathy)

With Treatment:

Prognostic Factors

Favourable Prognosis:

• First episode of AUR
• Identifiable and reversible precipitant (medications, constipation, UTI)
• Small prostate volume (less than 30ml)
• Lower residual volume (less than 800ml)
• Successful first TWOC
• Younger age

Poor Prognosis:

• Spontaneous AUR (no identifiable precipitant)
• Previous episodes of AUR
• Large residual volume (> 1000ml)
• Large prostate volume (> 50ml)
• High-pressure chronic retention
• Neurological cause
• Failed TWOC

Long-Term Outcomes

The REDUCE trial demonstrated that in men at risk of AUR due to BPH, 5-alpha reductase inhibitors (dutasteride) reduce the risk of AUR by 57% over 4 years. [15] Combination therapy (alpha-blocker + 5-ARI) provides additive benefit for symptom control and AUR prevention.

---

12. Prevention

Primary Prevention

In Men with BPH/LUTS:

• Alpha-blockers reduce AUR risk (relative risk reduction ~40%) [15]
• 5-alpha reductase inhibitors reduce AUR risk by 50-57% over 4 years [15]
• Combination therapy (alpha-blocker + 5-ARI) most effective for large prostates

Perioperative Prevention: [12]

• Avoid excessive IV fluids
• Minimise opioid use where possible
• Early mobilisation
• Consider prophylactic alpha-blocker in high-risk patients (previous retention, significant LUTS, BPH)

Medication Review:

• Avoid anticholinergics in men at risk
• Use caution with opioids, antihistamines, alpha-agonists

Secondary Prevention (After First Episode)

• Continue alpha-blocker for 4-6 weeks post-successful TWOC
• Address modifiable risk factors (constipation, medication review)
• Consider 5-ARI if large prostate (> 30-40ml)
• Urology follow-up for consideration of surgical intervention

---

13. Evidence and Guidelines

Key Guidelines

Landmark Trials

ALFAUR Trial (2004): [5]

• Design: Randomised, double-blind, placebo-controlled
• Population: 357 men with first episode AUR
• Intervention: Alfuzosin 10mg OD vs placebo for 3 days
• Outcome: TWOC success 61.9% vs 47.9% (p=0.03)
• Impact: Established alpha-blockers as standard of care before TWOC

REDUCE Trial (2010): [15]

• Design: Randomised, double-blind, placebo-controlled
• Population: 6,729 men with elevated PSA and BPH
• Intervention: Dutasteride 0.5mg OD vs placebo for 4 years
• Outcome: 57% reduction in AUR risk; 48% reduction in surgery
• Impact: 5-ARIs prevent AUR in men at high risk

MTOPS Trial (2003): [18]

• Design: Randomised, placebo-controlled
• Population: 3,047 men with BPH
• Intervention: Doxazosin, finasteride, combination, or placebo
• Outcome: Combination therapy reduced clinical progression by 66%
• Impact: Combination therapy for men with large prostates

Evidence Quality Summary

---

14. Exam-Focused Content

Common Exam Questions

1. "What are the causes of acute urinary retention?"
2. "Describe your management of a 70-year-old man presenting with AUR."
3. "What is post-obstructive diuresis and how would you manage it?"
4. "What are the indications for suprapubic catheterisation?"
5. "How do alpha-blockers work in BPH?"
6. "What are the predictors of successful TWOC?"
7. "What are the differences between acute and chronic urinary retention?"
8. "How would you investigate and manage suspected cauda equina syndrome?"

Viva Points

Viva Point: Opening Statement: "Acute urinary retention is the sudden painful inability to void despite a full bladder, most commonly caused by benign prostatic hyperplasia in men. It is a urological emergency requiring immediate bladder drainage via catheterisation."

Key Points to Mention:

1. BPH is the commonest cause (53-70%); look for precipitants (drugs, constipation, infection)
2. Rule out neurological emergency (cauda equina)—bilateral leg symptoms, saddle anaesthesia require emergency MRI
3. Catheterise and record residual volume; start alpha-blocker (tamsulosin 400mcg OD)
4. TWOC in 2-3 days; alpha-blockers improve success from ~30% to ~60% (ALFAUR trial)
5. High-pressure chronic retention needs monitoring for post-obstructive diuresis

Evidence to Cite:

• ALFAUR trial: Alpha-blockers increase TWOC success by 15-20%
• REDUCE trial: 5-ARIs reduce AUR risk by 57%
• Incidence: 2.2 per 1,000 man-years; 10% lifetime risk > 70 years

Common Mistakes

❌ Mistakes that fail candidates:

• Missing neurological red flags (cauda equina syndrome)
• Checking PSA in acute retention (falsely elevated)
• Clamping catheter to "gradually decompress" (no evidence; delays treatment)
• Forgetting to replace foreskin (paraphimosis)
• Not starting alpha-blocker before TWOC
• Forcing catheter despite resistance (urethral trauma)
• Discharging high-pressure retention without monitoring

Model Answers

Q: "A 72-year-old man presents to ED unable to pass urine for 8 hours with suprapubic pain. How would you manage him?"

A: "This is likely acute urinary retention until proven otherwise. My immediate priorities are:

Assessment:

• Brief focused history: Duration, precipitants (medications, constipation, recent surgery), LUTS history, neurological symptoms
• Examination: Vital signs, abdominal examination for palpable bladder, DRE for prostate size and rectal loading, neurological examination if any concern for cauda equina
• Bedside bladder scan to confirm retention (> 300ml)

Exclusion of Emergency:

• I would specifically ask about and examine for leg weakness, saddle numbness, and faecal incontinence—if present, this is cauda equina syndrome requiring emergency MRI spine

Management:

• Urethral catheterisation using aseptic technique with 12-14F Foley catheter
• Document residual volume
• Send urine for MC&S if cloudy
• Check U&Es—if elevated creatinine, I would be concerned about high-pressure chronic retention

Following catheterisation:

• Start tamsulosin 400mcg OD to improve TWOC success
• If residual > 1000ml or renal impairment, I would arrange renal USS and monitor for post-obstructive diuresis (output > 200ml/hr)
• Plan for TWOC in 2-3 days with alpha-blocker
• Arrange urology outpatient follow-up

If catheterisation fails:

• Senior or urology SpR attempt with Coudé catheter
• If still unsuccessful, suprapubic catheter insertion"

---

15. Patient/Layperson Explanation

What is Acute Urinary Retention?

Acute urinary retention (AUR) means you suddenly cannot pass urine, even though your bladder is very full. This causes severe pain and discomfort in your lower tummy. Think of it like a blocked drain—the water builds up but cannot flow out.

What Causes It?

The most common cause in men is an enlarged prostate gland (called benign prostatic hyperplasia or BPH). The prostate sits around the tube that carries urine from your bladder, and as it enlarges with age, it can squeeze this tube shut.

Other causes include:

• Certain medications (cold remedies, painkillers, some bladder medications)
• Severe constipation pressing on the bladder
• Urine infections
• After operations (especially under general anaesthetic)
• Nerve problems affecting the bladder

How is it Treated?

Immediate Relief: A thin tube (catheter) is passed through your water pipe into the bladder to drain the urine. This gives immediate relief from pain. The amount of urine drained is measured and helps us understand the severity.

Medication: You will be given tablets called alpha-blockers (usually tamsulosin). These relax the prostate and bladder neck muscles, making it easier to pass urine when we remove the catheter.

Trial Without Catheter (TWOC): After 2-3 days on the tablets, we remove the catheter to see if you can pass urine naturally. About half of men succeed first time. If not, we may try again or discuss other options including surgery.

Surgery: If retention keeps happening, an operation to reduce the size of the prostate (called TURP) may be recommended. This is very effective and usually resolves the problem.

What to Expect

• A catheter draining your bladder gives immediate pain relief
• You may go home with a catheter and leg bag for a few days
• You will return in 2-3 days for the catheter to be removed
• Continue taking the tablets as prescribed
• About half of men pass urine successfully; others may need further treatment

When to Seek Urgent Help

Call 999 or go to A&E if you:

• Cannot pass urine and have lower tummy pain
• Have a catheter that is blocked or not draining
• Develop fever, confusion, or feel very unwell with a catheter
• Have leg weakness, numbness, or difficulty controlling your bowels (this is a medical emergency)

Looking After Your Catheter

• Keep the drainage bag below your bladder level
• Empty the bag regularly (when 2/3 full)
• Drink plenty of fluids (1.5-2 litres per day)
• Clean around the catheter with soap and water daily
• Contact your GP or the urology team if: catheter blocks, falls out, you develop fever, or urine becomes very dark or bloody

---

16. References

1. Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis. 2004;7(1):32-37. doi:10.1038/sj.pcan.4500700 PMID: 14999234

2. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481-487. doi:10.1016/s0022-5347(01)64508-7 PMID: 9224329

3. Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the Health Professionals Followup Study. J Urol. 1999;162(2):376-382. doi:10.1016/s0022-5347(05)68571-8 PMID: 10411041

4. Hammarsten J, Lindqvist K. Suprapubic catheter following transurethral resection of the prostate: a way to decrease the number of urethral strictures and improve the outcome of operations. J Urol. 1992;147(3):648-651. doi:10.1016/s0022-5347(17)37337-x PMID: 1538451

5. McNeill SA, Hargreave TB; Members of the Alfazosin Once Daily Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol. 2004;171(6 Pt 1):2316-2320. doi:10.1097/01.ju.0000127445.47596.10 PMID: 15126810

6. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. 2005;95(3):354-357. doi:10.1111/j.1464-410X.2005.05299.x PMID: 15679793

7. Emberton M, Anson K. Acute urinary retention in men: an age old problem. BMJ. 1999;318(7188):921-925. doi:10.1136/bmj.318.7188.921 PMID: 10102863

8. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-388. doi:10.2165/00002018-200831050-00002 PMID: 18422378

9. Vaughan ED Jr, Gillenwater JY. Recovery following complete chronic unilateral ureteral occlusion: functional, radiographic and pathologic alterations. J Urol. 1971;106(1):27-35. doi:10.1016/s0022-5347(17)61219-3 PMID: 5570286

10. Ahn UM, Ahn NU, Buchowski JM, et al. Cauda equina syndrome secondary to lumbar disc herniation: a meta-analysis of surgical outcomes. Spine. 2000;25(12):1515-1522. doi:10.1097/00007632-200006150-00010 PMID: 10851100

11. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi:10.1002/nau.20798 PMID: 19941278

12. Baldini G, Bagry H, Aprikian A, Carli F. Postoperative urinary retention: anesthetic and perioperative considerations. Anesthesiology. 2009;110(5):1139-1157. doi:10.1097/ALN.0b013e31819f7aea PMID: 19395856

13. Fitzpatrick JM, Desgrandchamps F, Adjali K, et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int. 2012;109(1):88-95. doi:10.1111/j.1464-410X.2011.10430.x PMID: 21615852

14. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008;20 Suppl 3:S11-18. doi:10.1038/ijir.2008.55 PMID: 19002119

15. Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621. doi:10.1016/j.juro.2007.09.084 PMID: 18082216

16. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. doi:10.1016/j.juro.2008.03.058 PMID: 18499179

17. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. 2024. https://uroweb.org/guidelines/non-neurogenic-male-luts

18. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656 PMID: 14681504

19. NICE Clinical Knowledge Summaries. Urinary retention in men. National Institute for Health and Care Excellence. 2023. https://cks.nice.org.uk/topics/urinary-retention-in-men/

20. Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77(5):643-650. PMID: 18350762

---

Last Reviewed: 2025-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists for emergency situations.